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Recombinant bacterial vaccines must be safe, efficacious, and well tolerated, especially when administered
to newborns and infants to prevent diseases of early childhood. Many means of attenuation have been shown
to render vaccine strains susceptible to host defenses or unable to colonize lymphoid tissue effectively, thus
decreasing their immunogenicity. We have constructed recombinant attenuated Salmonella vaccine strains that
display high levels of attenuation while retaining the ability to induce high levels of immunogenicity and are
well tolerated in high doses when administered to infant mice as young as 24 h old. The strains contain three
means of regulated delayed attenuation, as well as a constellation of additional mutations that aid in enhancing
safety, regulate antigen expression, and reduce disease symptoms commonly associated with Salmonella infec-
tion. The vaccine strains are well tolerated when orally administered to infant mice 24 h old at doses as high
as 3.5  108 CFU.
Recombinant attenuated Salmonella vaccines (RASV) must
decrease disease symptoms associated with infection but must
also elicit a robust and lasting immune response to the vaccine.
Unfortunately, many of the disease symptoms are caused by
the same pathogenic strategies of Salmonella that are also
needed for delivery of the antigen to effector lymphoid tissue.
The ability of Salmonella to colonize the gut-associated lym-
phoid tissues (GALT) and adhere to and invade the intestinal
epithelium has been implicated in the success of live attenu-
ated vaccines (7); however, many means of attenuation render
the bacteria unable to survive and withstand host stresses, and
thus, they fail to reach the GALT in sufficient numbers to
stimulate robust mucosal, systemic, and cellular immune re-
sponses (reviewed by Curtiss et al. [13]). We have developed
five means of regulated delayed attenuation (13) in order to
retain near-wild-type abilities to reach the GALT, but after
several rounds of replication in host tissues, the bacterium
loses its ability to survive or withstand host stresses. Such a
recombinant Salmonella vaccine strain, which contains multi-
ple means of regulated delayed attenuation and is also unable
to cause the disease symptoms associated with infection, would
hopefully be a highly effective vaccine that could be distributed
to a heterogenous population of different ages and various
health and nutritional states.
We describe here the construction of attenuated Salmonella
enterica serovar Typhimurium vaccine strains that display a
phenotype of regulated delayed attenuation in vivo, that have
been further genetically altered for the safe and efficacious
delivery of antigens, and that are well tolerated when admin-
istered to infant mice. Regulated delayed attenuation is
achieved through arabinose-controlled expression of the fur,
crp, and phoPQ genes. It has been shown previously that mu-
tations in the fur, crp, and phoPQ genes are attenuating and
immunogenic in adult female BALB/c mice (10, 17, 20). The
fur gene encodes the Fur protein, which regulates iron uptake
and acquisition (2); the crp gene, encoding the cyclic AMP
(cAMP) receptor protein, is required for the transcription of
many genes involved in the breakdown and transport of me-
tabolites (23); and the phoPQ genes are needed for Salmonella
survival in macrophages (16, 22, 33). It has been shown previ-
ously that mutations in the pmi gene, which encodes phospho-
mannose isomerase, responsible for synthesizing an intact li-
popolysaccharide (LPS) O antigen, are also attenuating when
strains are grown in the absence of mannose (5, 11). In addi-
tion to these attenuating mutations, we have investigated the
inclusion of mutations to lessen the inflammation of, and fluid
secretion by, the intestinal mucosa in order to enhance vaccine
safety and acceptability.
Our vaccine strains are derived from the highly virulent S.
Typhimurium strain UK-1 (12); the wild-type UK-1 strain 3761
has a 50% lethal dose (LD50) of 1.2  10
4 CFU when adminis-
tered orally to adult BALB/c mice. Attenuated UK-1 strains can
induce full protective immunity to challenge with S.Typhimurium
strain SL1344 in mice (46) and strain F98 in chickens (24), but
isogenic attenuated strains of SL1344 and F98, though able to
induce full protective immunity to their wild-type parents, are
unable to induce full protective immunity to the UK-1 strain
3761. One of our vaccine constructs, 9558, has essentially the
same mutations selected as Salmonella enterica serovar Typhi
vaccine vectors currently being tested in adult human volunteers.
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It contains three means of achieving regulated delayed attenua-
tion, as well as a constellation of additional mutations that aid in
efficacy, safety, and delivery of recombinant antigens. These ad-
ditional mutations are included in the vaccine vector strain to
increase the safety and tolerability of the vaccine for oral admin-
istration to infants. The inclusion of these mutations reduces
disease symptoms associated with infection, such as diarrhea and
inflammation in the gut, as revealed in studies of infection in
rabbit ileal loops. We show here the construction of these recom-
binant attenuated S. Typhimurium vaccine vector strains, and we
show that the strains are well tolerated by infant mice less than
24 h old at doses of more than 10,000 times the LD50 of UK-1 in
adult BALB/c mice and 10,000,000 times the LD50 in newborn
mice. The strain we constructed, S. Typhimurium 9558, has been
evaluated by other members of our group for safety (4) and
immunogenicity (31) in adult mice, and we describe its colonizing
ability and immunogenicity in infant mice in the companion paper
(40).
MATERIALS AND METHODS
Bacterial strains, media, and bacterial growth. The vaccine strains used in this
study were derived from the S. Typhimurium strain UK-1 3761 (12). All bac-
terial strains used are listed in Table 1. LB broth and agar (3) were most often
used as the complex rich media for the propagation of bacterial strains. Nutrient
broth (Difco), which does not contain any mannose or arabinose, was also used
to assess the synthesis of LPS O-antigen side chains and the activation of the
araC PBAD cassette. Sugar fermentation was confirmed by plating bacterial
strains onto MacConkey agar (Difco) containing either 0.2% mannose, 0.2%
arabinose, or 0.2% maltose. Bacterial titers from colonization studies were enu-
merated on MacConkey agar containing 1% lactose to differentiate between
Escherichia coli and S. Typhimurium. Siderophore production was evaluated on
CAS plates containing chrome azurol S with Fe3 and hexadecyltrimethyl am-
monium bromide (HDTMA) in a morpholinepropanesulfonic acid (MOPS;
Sigma-Aldrich, St. Louis, MO) agar (39). The ability of bacteria to form thin
aggregate fimbriae was evaluated by plating on Congo red agar.
Construction of bacterial mutant strains. S. Typhimurium mutant strains were
constructed using either P22HTint phage-mediated transduction or conjugation
using suicide vectors (27). Transductants were selected by growth on Lennox
agar (L agar) (30) plates containing either 25 g/ml chloramphenicol or 12.5
g/ml tetracycline. Transductants were resuspended in sterile buffered saline
gelatin (BSG) (8) and were streaked onto antibiotic-containing medium for
isolated colonies. Isolated colonies were inoculated into fresh Lennox broth (L
broth) and were grown to an optical density at 600 nm (OD600) of 0.6. Double
crossovers were selected by growth on L agar plates without NaCl or dextrose but
containing 5% sucrose and were subsequently screened for antibiotic sensitivity.
The alternate method of using conjugation to construct the strains was also
employed (37). Parental S. Typhimurium strains were mated on L agar plates
containing 50 g/ml of diaminopimelic acid (DAP) with the E. coli host strain
7213 harboring the relevant suicide vector. Transconjugants were selected by
growth on L agar containing antibiotics without DAP. Conjugations with asdA
TABLE 1. Bacterial strains used in this study
Strain no. Genotype Reference orstrain of origin











8848 Pfur33::TT araC PBAD fur 3761
8868 pmi-2426 (gmd-fcl)-26 8650
8882 relA1123 3761
8918 PphoPQ107::TT araC PBAD phoPQ 3761
8923 sopB1925 3761
9021 Pcrp527::TT araC PBAD crp 3761
9107 Pfur33::TT araC PBAD fur Pcrp527::TT araC PBAD crp 8848
9108 PphoPQ107::TT araC PBAD phoPQ Pcrp527::TT araC PBAD crp 8918
9109 Pfur33::TT araC PBAD fur PphoPQ107::TT araC PBAD phoPQ Pcrp527::TT araC
PBAD crp
9000
9135 Pfur33::TT araC PBAD fur Pcrp527::TT araC PBAD crp pmi-2426 9107
9241 pabA1516 pabB232 asdA16 araBAD23 relA198::araC PBAD lacI TT 45
9295 pabA1516 pabB232 asdA16 relA198::araC PBAD lacI TT sopB1925 msbB48 9241
9373 pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur Pcrp527::TT araC PBAD crp
asdA21::TT araC PBAD c2 araE25 araBAD23 relA198::araC PBAD lacI TT
9352
9402 pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur Pcrp527::TT araC PBAD crp
asdA21::TT araC PBAD c2 araE25 araBAD23 relA198::araC PBAD lacI TT
sopB1925
9373
9513 pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur Pcrp527::TT araC PBAD crp
asdA21::TT araC PBAD c2 araE25 araBAD23 relA198::araC PBAD lacI TT
sopB1925 agfBAC811
9402
9554 pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur Pcrp527::TT araC PBAD crp
asdA21::TT araC PBAD c2 araE25 araBAD23 relA198::araC PBAD lacI TT
sopB1925 agfBAC811 msbB48
9513
9558 pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur Pcrp527::TT araC PBAD crp
asdA27::TT araC PBAD c2 araE25 araBAD23 relA198::araC PBAD lacI TT
sopB1925 agfBAC811
9513
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mutant strains were plated onto antibiotic-containing medium containing DAP
and colicin B to inhibit E. coli growth. Defined deletion mutations with and
without insertions were confirmed by PCR and phenotypic verification (11, 13).
Table S1 in the supplemental material lists the steps for the construction of
9558.
Molecular and phenotypic characterization of 9558 and its ancestor 9373.
All deletions and deletion-insertion mutations were confirmed by PCR amplifi-
cation. (See Table S2 in the supplemental material for oligonucleotide se-
quences.) Diagrams of deletion and deletion-insertion mutations are available
elsewhere (13, 31). The Pfur81::TT araC PBAD fur and Pcrp527::TT araC PBAD
crp regulated delayed attenuation deletion-insertion mutations were verified as
described by Curtiss et al. in 2009 (13). The pmi-2426 mutation results in a loss
of O-antigen side chain synthesis when strains are grown in nutrient broth
containing no mannose, but the mutant is able to synthesize the side chains in the
presence of 0.2% mannose (11). The LPS profiles of 9373, 9554, and 9558
grown in nutrient broth in the presence or absence of 0.2% mannose were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and silver staining. The araBAD23 and araE25 mutations were con-
firmed by lack of fermentation of arabinose (by plating onto MacConkey plates
containing 0.2% arabinose), in comparison with wild-type UK-1 3761, which is
able to utilize and ferment arabinose, and by inability to grow on minimal agar
supplemented with threonine, methionine, and DAP and containing arabinose as
the sole carbon source. The asdA27::TT araC PBAD c2 deletion-insertion mu-
tation was confirmed by the inability to grow in LB broth in the absence of 50
g/ml of DAP. C2 synthesis was confirmed by Western blot analysis of C2
protein when strains were grown in nutrient broth in the presence or absence of
0.2% arabinose. LacI synthesis due to the presence of the relA198::araC PBAD
lacI TT deletion-insertion mutation was confirmed by Western blot analysis of
LacI protein when strains were grown in nutrient broth in the presence or
absence of 0.2% arabinose. When the Asd balanced-lethal (18, 34) vaccine
vector plasmid pYA4088 was introduced into 9373, 9554, and 9558, PspA
synthesis under the control of the Ptrc promoter was correlated with a decrease
in LacI synthesis (31, 45). The presence of PspA was determined by Western blot
analysis. The sopB1925, msbB48, and (gmd-fcl)-26 mutations were con-
firmed through PCR amplification. The agfBAC811 mutation was confirmed by
the absence of Agf fimbriae as detected by growth on Congo red agar.
Electroporation of Salmonella strains with plasmids pYA3802 and pYA4088.
The balanced-lethal (18, 34) Asd plasmid vectors pYA3802 and pYA4088 were
constructed by cloning the DNA sequence encoding amino acids (aa) 3 to 285 of
pneumococcal surface protein A (PspA) from Streptococcus pneumoniae strain
Rx1 into the EcoRI and HindIII restriction enzyme sites of pYA3620 (11) and
pYA3493 (28) as previously described (45). Salmonella strains were grown aer-
obically in LB broth containing 50 g/ml DAP and 0.2% mannose to an OD600
of 0.6 and were prepared for electroporation using standard methods. Strains
containing the Asd plasmid were selected on LB agar containing 0.2% mannose
without DAP. After transformation with pYA4088, the S. Typhimurium vaccine
vector strains were grown in LB broth with 0.2% mannose and 0.2% arabinose.
Strains were verified for synthesis of complete LPS by silver staining of 10%
SDS-PAGE gels (25) to screen against the inadvertent selection of rough vari-
ants. Synthesis of PspA protein was verified using an anti-PspA antibody raised
in rabbits for Western blot analysis against whole-cell lysates. Regulation of
PspA synthesis by the arabinose-regulated lacI gene was verified by Western blot
analysis against whole-cell lysates grown in nutrient broth with and without 0.2%
arabinose.
Measurement of fluid secretion using rabbit ileal loops. New Zealand White
rabbits were fasted overnight and then anesthetized with isoflurane through an
endotracheal tube, and the ileum was exposed and then ligated into several loops
5 to 6 cm long using 1-cm spacers. S. Typhimurium strains were injected into
separate loops in a volume of 1 ml at a titer of 1  109 CFU. LB broth was
injected into one of the loops as a control. The abdominal musculature was
closed using 3-0 chromic gut sutures, and the skin was closed with 3-0 ethilon
sutures. Rabbits were maintained in a thermal blanket at 37°C. After 8 h, each
rabbit was euthanized with an overdose of sodium pentobarbital. The abdomen
was reopened, and the fluid within the ligated loops was collected, the volume
measured, and the bacterial content enumerated. The loops were fixed in 10%
formalin and subjected to histopathological examination.
Animal experimentation. Six-week-old female and male BALB/c mice to be
used as breeders were purchased from Charles River Laboratories (Wilmington,
MA) and housed according to Arizona State University IACUC-approved caging
and protocols. For immunization studies with adult mice, we purchased 6- to
7-week-old female BALB/c mice and held them for 1 week so that they could
acclimate prior to use. All animals were housed in biosafety level 2 (BSL-2)
containment with filter bonnet-covered cages. To produce infant mice, two fe-
male mice were placed in the same cage with one male mouse for breeding.
Pregnant female mice were placed in separate cages prior to the birth of pups.
The bacterial inocula were prepared as follows: 16- by 150-mm tubes with 5 ml
of LB broth containing 0.2% mannose and 0.2% arabinose were inoculated with
bacterial strains and incubated statically at 37°C for 18 h. The cultures were
diluted 1:50 into fresh prewarmed LB broth with 0.2% mannose and 0.2%
arabinose and were grown with aeration (180 rpm) at 37°C to an OD600 of 0.8 to
0.85. Cultures were pelleted at 4,500  g and were resuspended in BSG at the
densities required to produce the desired dose in the appropriate volume. Adult
mice were deprived of food and water for 6 h before oral inoculation, and food
and water were returned 30 min after oral inoculation. Adult mice were orally
inoculated with 20 l of the appropriate dose. To orally inoculate infant mice for
the evaluation of the various S. Typhimurium strains, the mother mouse was
placed in a separate cage from the pups, and the pups were inoculated with 2.5
l to 10 l of culture. Pups were monitored until the culture was swallowed. Pups
inoculated on the day of birth received 2.5 l of bacteria; 1- to 3-day-old pups
received 5 l of bacteria; and pups 3 days to 1 week old were inoculated with 10
l of bacteria. Pups were returned to the original position in the nest. The
mother was held in the investigator’s hands for a few moments so that she would
gain the smell of the gloves. Then she was placed back in the cage with her pups
and was monitored for abnormal and suspicious activity, such as removing cer-
tain pups from the nest. In other cases, we left a glove in the cage in order to
acclimate the mother to the glove odor. Once the mother began to eat and drink,
the cage was placed back in the rack. Pups were monitored for death every 24 h
for 30 days. Sometimes, with large litters, the mother cannibalized some mice to
reduce the litter size.
RESULTS
Construction of S. Typhimurium strains with individual
mutations and combinations of mutations. With the ultimate
objective of constructing a vaccine strain that would be safe
and nonreactogenic in newborn and infant mice, we generated
a number of derivatives of the wild-type UK-1 strain 3761
(Table 1) with the msbB48 mutation, to render lipid A non-
toxic yet able to be an agonist for TLR4 in mice (41), and with
the sopB1925 mutation, to decrease fluid secretion in the gut
of the mammalian host, with the effects of lessening both the
frequency and severity of diarrhea and decreasing neutrophil
accumulation in the intestine, thereby reducing inflammation
(19). We also constructed strains with mutations that conferred
a phenotype of regulated delayed attenuation in vivo (13).
These include strains with the pmi-2426 mutation, which
eliminates phosphomannose isomerase so that LPS O-antigen
synthesis ceases in vivo, due to the lack of availability of free
nonphosphorylated mannose. This renders strains more sensi-
tive to complement-mediated cytotoxicity and to killing by
phagocytosis (11). Three other types of regulated delayed at-
tenuation have been conferred on some strains by deletion of
the promoters for the fur, crp, and phoPQ virulence genes
and their replacement by a tightly regulated araC PBAD
cassette (29). The resulting Pfur81::TT araC PBAD fur,
Pcrp527::TT araC PBAD crp, and PphoPQ107::TT araC PBAD
phoPQ deletion-insertion mutations have been diagrammed
in other publications (13, 31) and have been introduced into a
number of strains (Table 1).
The sopB and msbB mutations decrease fluid secretion and
inflammation in rabbit ileal loops. The Salmonella sopB gene
encodes an inositol phosphate phosphatase that is secreted
by the bacteria into host intestinal epithelial cells via the
type III secretion system encoded by Salmonella pathoge-
nicity island 1 (SPI-1), causing an increase in chloride se-
cretion from the cell, resulting in a water efflux, fluid secre-
tion, and subsequent diarrhea that is commonly associated
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with Salmonella infection (15, 35). Other work has shown
that sopB has a role in neutrophil accumulation in the calf
intestine and thus leads to a population of inflammatory
cells in the ileum (19). The msbB gene encodes an acyltrans-
ferase that is responsible for the secondary acyl substitution
onto lipid A and has been shown to play a significant role in
the inflammation and endotoxicity in the gut that are associ-
ated with infection (42). Patients infected with Salmonella who
have inflamed intestines report pain, and since the vaccines we
are developing are to be administered to and tolerated by
infants, the roles of both sopB and msbB mutations in po-
tentially decreasing fluid secretion, inflammation, and endo-
toxicity in the gut would be advantageous. We therefore eval-
uated the effects of the sopB1925 and msbB48 mutations on
fluid secretion and inflammation in rabbit ileal loops. The
volume of fluid was decreased in ileal loops injected with the
sopB1925 (8923) and msbB48 (8573) mutants in compar-
ison to those injected with the wild-type parent strain, as shown
in Fig. 1A. Hematoxylin-and-eosin staining of sections of the
ileal loops showed a decrease in the presence of inflammatory
infiltrates, as well as a decrease in the level of destruction of
the intestinal epithelium, in the loop injected with 8923
sopB1925 (Fig. 1C) or 8573 msbB48 (Fig. 1D) in compar-
ison with the loop injected with wild-type 3761 UK-1 (Fig.
1B). It is thus desirable to add the sopB1925 mutation and
mutations like the msbB48 mutation to future vaccine strains.
Since the msbB mutation modifies lipid A to render it an
antagonist for human TLR4 (21, 42), we will add other genetic
modifications to render lipid A noninflammatory while allow-
ing it to serve as an agonist for human TLR4.
FIG. 1. S. Typhimurium sopB1925 and msbB48 mutants decrease fluid secretion and inflammation in rabbit ileal loops. Five- to 6-cm-long
rabbit ileal loops were injected with 109 CFU of S. Typhimurium strains for 8 h, and the fluid secretion and histopathological changes in the ileum
were examined. (A) Fluid secretion induced by S. Typhimurium strains in rabbit ileal loops. ND, not detectable. Asterisks, P 
 0.05. (B to E)
Histopathological staining of rabbit ileal loops injected with S. Typhimurium strains or the L broth control. (B) Wild-type 3761 UK-1; (C) 8923
sopB1925; (D) 8573 msbB48; (E) L broth. Bar, 100 m.
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Mutant attenuation for infant and newborn mice. We initi-
ated studies with low doses of strains administered to 3-week-
old weaned mice so as to minimize animal deaths and reveal
which mutations would confer maximal safety and attenuation.
As we established levels of attenuation at different ages, we
increased the doses and decreased the ages of mice orally
infected. We also constructed and evaluated strains with mul-
tiple mutations. As revealed by the data in Table 2, strains with
single pmi-2426, Pfur33::TT araC PBAD fur, Pcrp527::TT
araC PBAD crp, or PphoPQ107::TT araC PBAD phoPQ muta-
tions are fully attenuated in 7- to 8-week-old BALB/c mice.
However, they are only partially attenuated at moderate doses
in 3-week old weaned mice and are less attenuated in younger
mice (Table 2). Strains with two or three mutations conferring
regulated delayed attenuation led to complete attenuation in
3-week-old mice (data not shown) and increasingly better at-
tenuation in younger mice (Table 3). We used the 9241
pabA1516 pabB232 vaccine strain as the parental strain for
addition of the sopB1925 and msbB48 mutations, since
these attenuating pab mutations are not fully attenuating in
infant mice, as they are in adult mice (45). Inclusion of the
sopB1925 and msbB48 mutations in 9241 (9295) also
contributed improved tolerability for infant mice (Table 3).
Construction of the S. Typhimurium vaccine strain 9558.
Based on the results described above and on those of other
studies with additional mutant strains, we designed an S. Ty-
TABLE 2. Attenuation of orally administered S. Typhimurium strains with single mutations displaying regulated delayed
attenuation in mice of different agesa
Strain Genotype Sugar in medium (%) Age of mice Inoculating dose(CFU)
No. of survivors/
total no.
8650 pmi-2426 Mannose (0.5) 7–8 wk 1.1  106 5/5
Mannose (0.1) 3 wk 1.0  104 3/4
2 wk 7.0  105 3/3
4 days 1.0  105 0/4
8848 Pfur33::TT araC PBAD fur Arabinose (0.2) 7–8 wk 9.0  10
8 5/5
3 wk 1.0  104 4/4
2 wk 5.0  105 2/5
1 wk 7.0  105 0/5
4 days 1.0  105 0/4
8918 PphoPQ107::TT araC PBAD phoPQ Arabinose (0.2) 7–8 wk 1.0  10
9 5/5
Arabinose (0.1) 3 wk 1.0  104 5/5
2 wk 6.0  105 3/5
1 wk 7.0  105 0/5
4 days 1.0  105 0/5
9021 Pcrp527::TT araC PBAD crp Arabinose (0.2) 7–8 wk 1.0  10
9 5/5
Arabinose (0.1) 2 wk 6.0  105 1/5
1 wk 7.0  105 0/4
4 days 1.0  105 0/3
a Strains were grown in LB broth containing the percentage of sugar indicated. Mice were orally inoculated as described in Materials and Methods and were observed
for 30 days postinoculation.
TABLE 3. Attenuation of orally administered S. Typhimurium strains with multiple mutations displaying
regulated delayed attenuation in mice of decreasing agesa





9107 Pfur33::TT araC PBAD fur Pcrp527::TT araC PBAD crp 2 wk 1.3  10
8 5/5
9108 PphoPQ107::TT araC PBAD phoPQ Pcrp527::TT araC PBAD crp 1 wk 1.1  10
6 3/3
9109 Pfur33::TT araC PBAD fur PphoPQ107::TT araC PBAD phoPQ
Pcrp527::TT araC PBAD crp
1 wk 1.2  108 4/4
4 days 5.7  107 5/5
9135 Pfur33::TT araC PBAD fur Pcrp527::TT araC PBAD crp pmi-2426 2 wk 2.4  10
9 7/7
1 wk 1.0  108 2/4
1.0  107 4/4
2 days 1.5  104 3/3
9241 harboring pYA3802 pabA1516 pabB232 asdA16 araBAD23 relA198::araC PBAD
lacI TT
2 days 6.1  108 0/2
6.1  107 0/2
6.1  106 1/3
9295 harboring pYA3802 pabA1516 pabB232 asdA16 araBAD23 relA198::araC PBAD
lacI TT sopB1925 msbB48
2 days 8.9  108 0/2
8.9  107 2/3
8.9  106 2/2
a 9107, 9108, and 9109 were grown in LB broth with 0.2% arabinose, and 9135 was grown in LB broth with 0.2% mannose. Mice were orally inoculated as
described in Materials and Methods and were observed for 30 days postinoculation.
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phimurium vaccine strain to serve as a standard for compari-
son with S. Typhi vaccine strains to be evaluated in human
volunteers. This strain, 9558, would then be used to obtain
safety and efficacy data to justify human clinical trials. The
construction lineage of 9558 is described in Table S1 in the
supplemental material. 9558 contains three means for achiev-
ing regulated delayed attenuation in vivo, as described previ-
ously (11, 13). 9558 also contains a constellation of gene
deletions and deletion-insertion mutations that enhance the
safety and efficacy of the vaccine strain. Data not previously
reported on the virulence in adult mice of strains with individ-
ual deletion mutations that are present in the various multiple
mutant strains are provided in Table 4. Findings on the attenua-
tion and immunogenicity in adult mice of strains with other indi-
vidual deletion and deletion-insertion mutations present in 9558
have been provided in other articles (11, 13). The pmi-2426
mutation and the deletion-insertion mutations Pfur81::TT araC
PBAD fur and Pcrp527::TT araC PBAD crp achieve regulated de-
layed attenuation such that growth in a medium with 0.1% man-
nose and 0.05 to 0.2% arabinose yields a strain that can withstand
the host-imposed stresses encountered after oral delivery and
enables maximal invasion and colonization of lymphoid effector
tissues prior to display of the attenuated phenotype as a conse-
quence of cell division in vivo (11, 13). It should be noted that we
are using the Pfur81::TT araC PBAD fur deletion-insertion muta-
tion rather than the Pfur33::TT araC PBAD fur construction
because the latter causes the synthesis of too much Fur protein
when the strain is grown in LB broth with 0.2% arabinose, and
that interferes with initial vaccine effectiveness (13). The ar
aBAD23 mutation prevents the bacteria from using arabinose
or breaking down arabinose in the cytoplasm, and the araE25
mutation allows for the retention of supplied arabinose in the
cytoplasm (26, 32). Both mutations thus enable the activation
of the araC PBAD cassette in strains with araC PBAD-regulated
deletion-insertion mutations for another cell division or so,
which increases colonization levels to further enhance the lev-
els of induced immunity. In addition, the inability to metabo-
lize arabinose precludes an undesirable pH drop during growth
in a medium with added arabinose. The deletion-insertion
mutation asdA27::TT araC PBAD c2 (an improvement over
the asdA18::TT araC PBAD c2 and asdA21::TT araC PBAD
c2 versions present in early 9558 ancestor strains) provides
the balanced-lethal host-vector system as previously described
(18, 34), and the arabinose-controlled synthesis of the C2 re-
pressor (38) can be used to achieve regulated delayed synthesis
of antigens controlled by the bacteriophage P22 PR or PL
promoter. Deletion of the asd gene imposes a requirement for
exogenously supplied diaminopimelic acid, an essential com-
ponent of the peptidoglycan layer of the bacterial cell wall. The
vaccine plasmid vector contains a wild-type copy of the asd
gene, thus complementing the deletion mutation in the host
strain, which allows the bacteria to grow without exogenous
DAP and ensures that the vector is maintained within the host
bacterial strain in vivo. This eliminates the need for antibiotic
resistance to maintain the plasmid, an important attribute,
since live bacterial vaccines should be susceptible to all anti-
biotics that might be used to control infection. The (gmd-
fcl)-26 mutation deletes the genes responsible for the enzymes
required for GDP-fucose synthesis, thus blocking the conver-
sion of GDP-mannose to GDP-fucose, and prevents colanic
acid production (1, 43). Stress conditions induced by cell wall
damage lead to the production of colanic acid and can allow
for the survival of asdA mutants. The presence of this mutation
also reduces the potential of the vaccine strain to form biofilms
(14). The deletion-insertion mutation relA198::araC PBAD
lacI TT inactivates the relA gene, which uncouples the occur-
rence of cell wall-less death from dependence on protein syn-
thesis (44). The arabinose-controlled synthesis of the LacI re-
pressor is used to achieve regulated delayed synthesis of
antigens under the control of the Ptrc promoter (S. Wang,
personal communication). The transcription terminators (TT)
present in several constructions prevent readthrough into ad-
jacent genes, which sometimes can interfere with normal func-
tions of adjacent genes. The sopB1925 mutation is included in
order to decrease fluid secretion in the gut of the mammalian
host so as to lessen the frequency of diarrhea and also serves to
decrease neutrophil accumulation in the intestine and thus
reduce inflammation. The agfBAC811 mutation reduces the
bacterium’s ability to form thin aggregative fimbriae (6) and
precludes the formation of biofilms on gallstones, which are
necessary for the establishment and maintenance of chronic
infection and for persistence in the gallbladder (36). The ar
aBAD23, relA, and sopB1925 mutations each contribute a
low level of attenuation to vaccine strains (Table 4) but have
no apparent adverse effect on the colonization of internal ef-
fector lymphoid tissues. The araE25, (gmd-fcl)-26, and ag
TABLE 4. Virulence (LD50) of S. Typhimurium strains with
deletion mutationsa
Strain Genotype Inoculating dose(CFU)
No. of survivors/
total no.
8878 agfBAC811 7.0  105 0/5
7.0  104 0/5
7.0  103 2/5
8767 araBAD23 5.0  105 5/10
5.0  104 5/10
5.0  103 10/10
8477 araE25 1.1  108 0/4
1.1  107 1/4
1.1  106 1/4
1.1  105 2/4
8831 (gmd-fcl)-26 7.0  105 1/8
7.0  104 4/8
7.0  103 5/8
8573 msbB48 8.0  105 4/14
8.0  104 13/14
8.0  103 13/14
8882 relA1123 9.0  106 2/9
9.0  105 4/9
9.0  104 7/8
8923 sopB1925 9.0  105 7/10
9.0  104 8/10
9.0  103 10/10
a Female BALB/c mice 6 to 7 weeks of age were orally immunized with the
indicated strains as described in Materials and Methods. Mice were observed for
30 days after inoculation.
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fBAC811 mutations have no effect on virulence (Table 4) or
colonization (data not shown).
9558 was constructed through the sequential deletion of
genes with or without insertions, as described in Table S1 in
the supplemental material. Two of the mutations have been
altered several times, due to discoveries affecting the virulence
and survival of the host strain in vivo (13) and the expression of
the repressor proteins, to achieve regulated delayed synthesis
of protective recombinant antigen in vivo. The Pfur81::TT
araC PBAD fur mutation was substituted for the Pfur33::TT
araC PBAD fur mutation after the discovery that overexpression
of Fur protein presumably resulted in iron starvation in the
intestinal tract so as to actually reduce colonization of the
GALT and internal lymphoid organs. Thus, reduced synthesis
of Fur by strains with the Pfur81::TT araC PBAD fur insertion-
deletion mutation resulted in improved colonization of lym-
phoid organs when strains were grown in LB broth containing
0.2% arabinose (13). The presence of the Pfur81::TT araC
PBAD fur construction, when bacteria were grown in the pres-
ence of 0.2% arabinose, resulted in an attenuated strain that
conferred complete protection upon challenge with the viru-
lent wild-type strain 3761 (13). The asdA mutation has also
undergone several alterations during the course of 9558 con-
struction. The strain originally contained a defined deletion of
the asdA gene (asdA33) that would serve in the balanced-
lethal host-vector system, but this was replaced with the dele-
tion-insertion mutation asdA18::TT araC PBAD c2, which
would allow for the regulated delayed expression of antigens
under the control of the P22 PL or PR promoter. The synthesis
of C2 was optimized for complete repression of the antigen in
the presence of 0.2% arabinose, and the resulting deletion-
insertion mutation is asdA27::TT araC PBAD c2.
Attenuation of 9558 and parent strains in infant mice. The
attenuation of 9373, 9554, and 9558 harboring pYA4088
was evaluated through oral inoculation of infant BALB/c mice
of various ages, ranging from the day of birth to 7 days (Table
5). The bacterial inoculum varied depending on the age of the
mice; however, all inocula administered were above the LD50
of 3761 in adult BALB/c mice. The strains were grown in LB
broth in the presence of 0.2% mannose and 0.2% arabinose.
The volume of inoculum administered to infant mice de-
pended on their age and ranged from 2.5 l to 10 l. At the
ages of 6 to 7 days, RASV strains 9373 and 9558 displayed
safety up to a dose of 109 CFU. In 2- to 4-day-old mice, 9558
displayed safety up to 3.0  108 CFU. 9558 displayed safety in
2-day-old infant mice at a dose roughly 27,000 times the LD50
of 3761 in adult BALB/c mice. It should be noted that large
litters of pups can result in cannibalization of some of the pups
by a first-time mother mouse. The addition of the sopB1925
and agfBAC811 mutations increases the safety of the strain,
as seen in the survival of mice inoculated on the day of birth
with 9373 at 2.2  106 CFU compared to that of mice of the
same age inoculated with 9558 at 3.5  108 CFU. Thus, the
infant mice are able to tolerate a higher dose of RASV inoc-
ulum when the sopB1925 and agfBAC811 mutations are
included, as in 9558. We also evaluated 9554, which has the
msbB48 mutation rather than the agfBAC811 mutation
present in 9558, and the strain was well tolerated in 2-day-old
and day-of-birth mice at doses of 4.7  107 CFU and 2.5  107
CFU, respectively. We also assayed infected pups for coloni-
zation of the GALT, and all strains showed colonization of the
spleen, liver, and intestine and persisted in tissues for at least
7 days (data not shown). The vaccine vector strain 9558 is
thus capable of colonizing infant mice, as reported by Shi et al.
(40), who also report on immunogenicity and the induction of
protection against S. pneumoniae challenges.
DISCUSSION
We describe here the analysis of means of attenuation of S.
Typhimurium in addition to other mutational alterations to
enhance the safety and acceptability of vaccine strains designed
TABLE 5. Virulence of RASV strains in infant micea
Strain Genotype Age of mice CFU/dose No. of survivors/total no.
9373 harboring
pYA4088
pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur
Pcrp527::TT araC PBAD crp asdA21::TT araC
PBAD c2 araE25 araBAD23 relA198::araC
PBAD lacI TT
6 days 8.8  108 4/4
8.8  108 4/4
8.8  107 4/4
3 days 4.4  107 4/4
2 days 5.4  107 6/6
5.7  108 5/6
Day of birth
(1–2 h)
2.2  106 5/6
9554 harboring
pYA4088
pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur
Pcrp527::TT araC PBAD crp asdA21::TT araC
PBAD c2 araE25 araBAD23 relA198::araC
PBAD lacI TT sopB1925 agfBAC811 msbB48
7 days 9.9  108 5/5
2 days 4.7  107 5/5
Day of birth 2.5  107 7/9b
9558 harboring
pYA4088
pmi-2426 (gmd-fcl)-26 Pfur81::TT araC PBAD fur
Pcrp527::TT araC PBAD crp asdA27::TT araC
PBAD c2 araE25 araBAD23 relA198::araC
PBAD lacI TT sopB1925 agfBAC811
7 days 9.9  108 11/11
4 days 3.0  108 6/6
2 days 3.3  108 11/11
Day of birth 3.5  108 13/15b
a All strains were grown in LB broth with 0.2% arabinose and 0.2% mannose and were orally inoculated into mice as described in Materials and Methods. Mice were
observed for 30 days postinoculation.
b The mother may have cannibalized two infants due to the large litter size.
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for the immunization of infant and newborn mice. Based on
data collected, we designed a vaccine strain that would satisfy
these safety objectives and allow the collection of data to justify
the use of recombinant attenuated S. Typhi strains of the same
genotype for the conduct of human clinical trials. The data
collected served as the basis for the construction and genetic
composition of 9558 and show that this strain is well tolerated
and safe in infant mice and newborn mice less than 24 h old.
The three means of achieving regulated delayed attenuation
(pmi-2426, Pfur81::TT araC PBAD fur, and Pcrp527::TT araC
PBAD crp) increase the safety of the vaccine by allowing a
near-wild-type ability to withstand host stresses and colonize
the GALT following oral inoculation yet rendering the bacte-
ria susceptible to host defenses after several rounds of repli-
cation in host tissue, due to reduced expression of the fur and
crp genes and loss of LPS O-antigen side chains (11, 13). These
methods of attenuation, in combination with mutations that (i)
reduce disease symptoms through reduction of fluid secretion
and inflammation in the gut (sopB1925 and msbB48), at
least in rabbits, (ii) allow bacteria to colonize effector lymphoid
tissues (but prevent them from establishing a persistent state in
the host) [(gmd-fcl)-26, agfBAC811], (iii) allow regulated
delayed synthesis of a recombinant protective antigen in lym-
phoid tissues (relA198::araC PBAD lacI TT), and (iv) enable
the establishment of a drug-sensitive balanced-lethal vector-
host system (asdA27::TT araC PBAD c2), yield a vaccine
strain that is safe, nonreactogenic, and hopefully effective in
inducing protective immunity in mice. In this regard, Li et al.
(31) have demonstrated that 9558 harboring pYA4088 is su-
perior to other attenuated S. Typhimurium vaccine strains in
inducing antibodies against the PspA antigen and protective
immunity to S. pneumoniae challenge in adult mice. In another
study, Bollen et al. (4) have demonstrated that the genotype of
9558 harboring pYA4088 very much lessens, if it does not
eliminate, the ability of S. Typhimurium to induce symptoms of
meningitis when administered at high doses to adult mice by
intranasal, oral, and intraperitoneal routes.
Additional mutations that further enhance the safety, effi-
cacy, and acceptability of vaccine derivatives of 9558 are cur-
rently under evaluation. These include mutations and special
vectors that will achieve total biocontainment through regu-
lated delayed lysis in vivo of the vaccine strains such that there
is no persistence in vivo and no survivors if the bacterium is
shed into the environment (29). Most notable is the replace-
ment of the msbB48 mutation. While the msbB48 mutation
acts as an agonist for TRL4 in mice (41), it serves as an
antagonist in humans (21, 42); thus, alternate genes are cur-
rently being evaluated in order to eliminate the toxicity of lipid
A yet enable lipid A to serve as an agonist for human TLR4.
Still other mutations to enhance lymphoid tissue colonization
levels and to synthesize recombinant antigens to higher levels
are being evaluated. In this regard, Xin et al. (45) have re-
ported multiple means to enhance type II secretion of recom-
binant protective antigens from S. Typhimurium vaccine
strains displaying regulated delayed synthesis of recombinant
antigens. It should be noted that the same mutations that are
present in 9558 have been constructed in parallel S. Typhi
strains for evaluation in humans. Since S. Typhi is host specific,
and S. Typhimurium infection results in a typhoid-like disease
in mice, we use S. Typhimurium in mice to simulate an S. Typhi
infection in humans. Nevertheless, we are cognizant of the
potential that results obtained with S. Typhimurium constructs
in mice may be misleading in predicting results in other animal
species or with similar S. Typhi strains in humans. The in vitro
and in vivo (in mice) characterizations of the S. Typhi strains
will be presented in a separate report. Further studies involving
more-detailed analysis of the immune response of infant mice
orally immunized with 9558 harboring pYA4088, as well as
the role of maternal immunization, have been conducted and
are presented by Shi et al. (40).
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